Gamma-secretase: from pathogenesis to therapeutics
- Yueming Li1
© Li; licensee BioMed Central Ltd. 2012
Published: 7 February 2012
Presenilin (PS) is the catalytic subunit of γ-secretase and mutations in this protein cause familial Alzheimer’s Disease (FAD). Moreover, γ-secretase has emerged as an appealing drug target for Alzheimer’s disease (AD) and cancer due to its central role in the generation of Aβ peptides and the regulation of Notch signaling. γ-Secretase is composed of at least four subunits: PS, Nicastrin, Aph1 and Pen2; with a total of 19 putative transmembrane domains.
Investigation of γ-secretase structure and function has been a formidable challenge because of its nature of intramembranal catalysis and macromolecular complex that requires novel chemical insights. We have developed a reconstituted system and small molecular probes that allow us to study the regulation of γ-secretase and to elucidate the mechanism of PS1 FAD mutations. We have reconstituted γ-secretase using a proteoliposomes system and provided the final proof that γ-secretase activity is an inherent property of PS. Moreover, we have demonstrated that PS mutations directly alter a subsite of γ-secretase active site and defined the action mechanism of γ-secretase modulators.
Our studies provide a molecular basis of PS1 mutations in AD pathogenesis and offer a unique approach to elucidate the reaction mechanism of γ-secretase, with the expectation that these efforts will lead to the development of effective therapies for AD and other human disorders.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.